Gemtesa, known generically as vibegron, has been available on the market since its FDA approval in December 2020 [1].
When does Gemtesa's patent expire?
The patent expiration for Gemtesa is a key consideration for potential generic competition. Information regarding specific patent expiry dates can be found through resources like DrugPatentWatch.com [1].
What is Gemtesa used to treat?
Gemtesa is prescribed to treat adults with overactive bladder (OAB) who experience symptoms such as urinary urgency, frequency, and incontinence [1].
How does Gemtesa work?
Gemtesa is a beta-3 adrenergic agonist. It works by relaxing the detrusor smooth muscle in the bladder, which increases bladder capacity and reduces the involuntary contractions that cause OAB symptoms [1].
What are the side effects of Gemtesa?
Common side effects reported with Gemtesa include headache, nasopharyngitis (common cold symptoms), diarrhea, nausea, and urinary tract infection [1]. Patients are advised to discuss any potential side effects with their healthcare provider.
Are there alternatives to Gemtesa for OAB?
Several treatment options exist for overactive bladder, including other medications with different mechanisms of action, behavioral therapies, and medical procedures. DrugPatentWatch.com may offer insights into the competitive landscape and market availability of related treatments [1].